T1	Disease	65 91	anaplastic lymphoma kinase
T2	Chemical	62 122	an anaplastic lymphoma kinase inhibitor ( crizotinib ) based
T3	Pharmacodynamic_phenotype	148 164	response rate in
T4	Disease	188 219	small cell lung cancer patients
T5	Disease	226 239	tumors harbor
T6	Genomic_variation	245 269	4 / ALK translocations .
R1	influences	Arg1:T1	Arg2:T2
R2	treats	Arg1:T1	Arg2:T4
R3	isAssociatedWith	Arg1:T1	Arg2:T6
R4	decreases	Arg1:T2	Arg2:T1
R5	treats	Arg1:T2	Arg2:T4
R6	isAssociatedWith	Arg1:T3	Arg2:T1
R7	isAssociatedWith	Arg1:T3	Arg2:T2
R8	treats	Arg1:T3	Arg2:T4
R9	isAssociatedWith	Arg1:T3	Arg2:T5
R10	isAssociatedWith	Arg1:T3	Arg2:T6
R11	isAssociatedWith	Arg1:T4	Arg2:T5
R12	isAssociatedWith	Arg1:T4	Arg2:T6
R13	influences	Arg1:T5	Arg2:T2
R14	isAssociatedWith	Arg1:T5	Arg2:T3
R15	isAssociatedWith	Arg1:T5	Arg2:T4
R16	isAssociatedWith	Arg1:T5	Arg2:T6
R17	influences	Arg1:T6	Arg2:T2
R18	influences	Arg1:T6	Arg2:T3
R19	isAssociatedWith	Arg1:T6	Arg2:T4
R20	isAssociatedWith	Arg1:T6	Arg2:T5
